MitoGel™ is potentially the first non-surgical, renal-sparing, local treatment for low-grade UTUC. MitoGel is a sustained release formulation of Mitomycin C in the upper urinary tract. UroGen has obtained Orphan Drug Designation for MitoGel for UTUC.

Read More >

VesiGel™ is potentially the first non-surgical, local chemoablation therapy for the treatment Low Grade NMIBC. VesiGel is a sustained release formulation of high dose Mitomycin C for the effective delivery and prolonged tissue exposure.

Read More >

Vesimune™ is a TLR-7 agonist-based formulation for local intravesical delivery.  Vesimune is being developed as a potential treatment for CIS. UroGen has obtained Orphan Drug Designation for Vesimune for the treatment of CIS.

 

Read More >

About UroGen Pharma

UroGen Pharma (formerly TheraCoat) is a clinical stage, biotechnology company, with the goal of transforming local therapy for urological pathologies. The Company is focusing on the development of novel pharmaceutical solutions for several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer, CIS bladder cancer and low-grade UTUC, an unmet medical need for which there are no FDA approved drugs.  UroGen Pharma’s drug candidates may have the potential to replace the burdensome and costly surgical interventions and shift the use of local drug treatment from adjuvant to first line therapy.

Read More >

Clinical Trials

UTUC

olympusThe OLYMPUS study

Optimized DeLivery of Mitomycin for Primary UTUC Study
CURRENTLY RECRUITING CENTERS IN THE US AND EUROPE

 

BLADDER CANCER

optimaThe OPTIMA study

OPTimized Instillation of Mitomycin for BlAdder Cancer Treament
CURRENTLY RECRUITING PATIENTS IN LEADING CENTERS IN EUROPE